AIM-100, an inhibitor of ACK1, can significantly inhibit TLR4/TLR7/TLR9-induced activation of macrophages and DCs and alleviates the TLRs-mediated inflammation and autoimmunity (Figure 8). This evidence concerns the gene TLR9 and Autoimmunity.